Swiss National Bank Sells 6,400 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Swiss National Bank lowered its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 8.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,500 shares of the company’s stock after selling 6,400 shares during the quarter. Swiss National Bank owned 0.20% of TransMedics Group worth $4,960,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Aigen Investment Management LP bought a new position in TransMedics Group in the 4th quarter valued at $212,000. Wealthcare Advisory Partners LLC grew its stake in TransMedics Group by 3.7% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 5,119 shares of the company’s stock valued at $388,000 after purchasing an additional 183 shares during the period. First Trust Advisors LP bought a new position in TransMedics Group in the 4th quarter valued at $2,390,000. First Light Asset Management LLC grew its stake in TransMedics Group by 72.4% in the 4th quarter. First Light Asset Management LLC now owns 265,097 shares of the company’s stock valued at $16,362,000 after purchasing an additional 111,328 shares during the period. Finally, Jennison Associates LLC bought a new position in TransMedics Group in the 1st quarter valued at $325,000. Institutional investors own 91.25% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on TMDX. Robert W. Baird began coverage on TransMedics Group in a research note on Wednesday, July 19th. They issued an “outperform” rating for the company. TheStreet upgraded TransMedics Group from a “d+” rating to a “c-” rating in a research note on Friday, August 4th. Oppenheimer increased their price target on TransMedics Group from $90.00 to $92.00 in a research note on Friday, August 4th. TD Cowen increased their price target on TransMedics Group from $95.00 to $110.00 and gave the stock an “outperform” rating in a research note on Friday, August 4th. Finally, William Blair reiterated an “outperform” rating on shares of TransMedics Group in a research note on Wednesday, July 19th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and an average price target of $85.00.

TransMedics Group Stock Up 1.7 %

Shares of NASDAQ TMDX opened at $65.35 on Thursday. TransMedics Group, Inc. has a 52 week low of $38.86 and a 52 week high of $99.63. The business has a 50-day simple moving average of $79.01 and a two-hundred day simple moving average of $76.43. The company has a quick ratio of 19.74, a current ratio of 20.70 and a debt-to-equity ratio of 3.48. The company has a market cap of $2.13 billion, a P/E ratio of -114.65 and a beta of 1.46.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.12. The firm had revenue of $42.46 million during the quarter, compared to the consensus estimate of $42.42 million. TransMedics Group had a negative return on equity of 9.98% and a negative net margin of 11.77%. The company’s revenue for the quarter was up 136.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.41) EPS. Research analysts anticipate that TransMedics Group, Inc. will post -0.51 earnings per share for the current fiscal year.

Insider Activity

In other TransMedics Group news, Director David Weill purchased 2,500 shares of the company’s stock in a transaction dated Tuesday, August 29th. The stock was purchased at an average price of $62.00 per share, for a total transaction of $155,000.00. Following the transaction, the director now owns 13,693 shares in the company, valued at approximately $848,966. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Waleed H. Hassanein sold 7,500 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $82.51, for a total transaction of $618,825.00. Following the transaction, the chief executive officer now directly owns 544,191 shares of the company’s stock, valued at approximately $44,901,199.41. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David Weill acquired 2,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 29th. The shares were purchased at an average cost of $62.00 per share, for a total transaction of $155,000.00. Following the completion of the acquisition, the director now owns 13,693 shares in the company, valued at approximately $848,966. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 22,974 shares of company stock worth $2,061,434. 6.70% of the stock is currently owned by insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.